Table 1 Demographic and clinical characteristics of study population.
From: Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
Global (n = 190) | Anti-TNF naïve (n = 105) | Previously treated with an anti-TNF (n = 85) | |
|---|---|---|---|
Male/female | 101 (53%)/89 (47%) | 58 (55%)/47 (45%) | 43 (51%)/42 (49%) |
Age, years | 44.39 ± 15.33 43.26 (33.61, 54.89) | 44.02 ± 16.69 42.9 (33.08, 54.9) | 44.85 ± 13.53 43.57 (34.32, 53.9) |
Disease duration, years | 9.32 ± 8.09 7.52 (2.99, 12.78) | 8.52 ± 8.19 6.25 (1.97, 2.79) | 10.31 ± 7.89 8.36 (4.79, 12.75) |
Disease extent (montreal classification) | |||
E1 (proctitis) | 7 (4%) | 4 (4%) | 3 (4%) |
E2 (left-side colitis) | 74 (39%) | 47 (45%) | 27 (32) |
E3 (extensive colitis) | 109 (57%) | 54 (51%) | 55 (64%) |
Concomitant autoimmune disease | 20 (10.5%) | 98 (93%) | 72 (85%) |
Concomitant immunosuppressants | 91 (48%) | 54 (51%) | 37 (44%) |
Concomitant corticosteroids | 72 (39%) | 37 (37%) | 35 (42%) |
Indication for golimumab | |||
Induction of remission | 172 (90%) | 102 (97%) | 70 (82%) |
Maintenance of remission | 16 (9%) | 2 (2%) | 14 (17%) |
Extraintestinal manifestations | 2 (1%) | 1 (1%) | 1 (1%) |
Induction dose | |||
200/100 mg | 184 (98%) | 103 (100%) | 81 (96.4%) |
Maintenance dose | |||
100 mg every 4 weeks | 87 (47%) | 50 (49%) | 37 (44%) |
50 mg every 4 weeks | 99 (53%) | 52 (51%) | 47 (56%) |
